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Phosphate binding gels: balancing phosphate adsorption and aluminum
toxicity. The phosphate binding capacity of five commercial aluminum
hydroxide phosphate—binding gels and two crystalline forms of alumi-
num hydroxide was studied by an in vitro procedure which simulated
passage through the stomach to the small intestine. The potential for
aluminum toxicity was estimated by determining the fraction of the
dose which was converted into soluble aluminum species by acid
neutralization at pH 3, 37°C. The commercial products varied widely
both in phosphate binding capacity and production of soluble aluminum
species. The evidence suggests that the ideal phosphate binder will have
a surface area small enough to minimize the formation of soluble
aluminum species during the gastric residence time but also large
enough to adsorb a clinically significant amount of phosphate.
One of the major goals in the treatment of chronic renal
failure patients is to reduce serum phosphate levels while
avoiding aluminum toxicity. Aluminum toxicity is most fre-
quently manifested as dialysis dementia [1—6] and osteomalacic
dialysis osteodystrophy [2, 7—9]. The most significant sources of
aluminum for dialysis patients are the dialysis fluid [2, 4—7, 10]
and orally administered aluminum hydroxide phosphate—bind-
ers [1, 3, 4, 10—12]. Renal patients are susceptible to aluminum
toxicity as they lack the normal means of eliminating aluminum
[1] which is absorbed through the membranes of the upper
gastrointestinal tract [11].
Aluminum hydroxide is administered to lower serum phos-
phate levels by adsorbing phosphate in the intestine. It is ideally
suited for this purpose as phosphate is specifically adsorbed by
aluminum atoms at the surface of aluminum hydroxide particles
[13], and in addition, soluble aluminum species, formed through
acid neutralization, readily react with phosphate ions to form
insoluble aluminum phosphate [14]. Thus, orally administered
aluminum hydroxide binds phosphate in the intestine regardless
of whether it leaves the stomach as unneutralized aluminum
hydroxide particles or as soluble aluminum species formed as a
result of acid neutralization. The soluble aluminum species may
also reprecipitate in the small intestine in the form of aluminum
hydroxide, which is also capable of adsorbing phosphate.
Soluble phosphate in the intestinal fluid is thus converted into
an insoluble form which is eliminated in the feces [1]. As an
Received for publication December 18, 1984,
and in revised form July 16, 1985
© 1986 by the International Society of Nephrology
equilibrium exists between serum phosphate and phosphate in
the intestinal fluid, removal of phosphate from the intestine will
result in a decrease in the serum phosphate concentration.
The term aluminum hydroxide, as applied to phosphate
binding gels, refers to an amorphous polymer—like material
which is produced by a precipitation process. The polymer
subunits are ring structures composed of six aluminum octahe-
drajoined by double hydroxide bridges [15]. The pH, rate of pH
change, and the anions present during precipitation greatly
affect the degree of polymerization. Nonhomogeneous precipi-
tation conditions produce polymers of various sizes resulting in
aluminum hydroxide of various surface areas [16]. Because
phosphate is specifically adsorbed by aluminum hydroxide,
adsorption of phosphate in the intestine is directly related to
surface area. Likewise, the rate of acid neutralization with the
concomitant formation of soluble aluminum species is also
directly related to the surface area, since protons attack the
accessible double hydroxyl bridges at the periphery of the
aluminum hydroxide polymers during acid neutralization [17].
The purpose of this study was to estimate the production of
soluble aluminum species during the gastric resident time
proposed for antacids [18] and the degree of phosphate binding
under in vitro conditions similar in terms of pH, volume and
phosphate concentration to those encountered when aluminum
hydroxide proceeds through the gastrointestinal tract from the
stomach to the intestine. Five products currently used as
phosphate binders by dialysis patients were studied along with
gibbsite and boehmite, crystalline forms of aluminum hydroxide
with known surface area. Gibbsite was chosen because it exists
as large, platy particles having a low surface area (Fig. 1A). In
contrast, boehmite may be obtained in the form of small
scroll—like particles which form a very porous aggregate having
a moderate surface area (Fig. IB).
Methods
The phosphate binders studied were obtained commercially'
Basaljel, Wyeth Laboratories, Inc., Philadelphia, Pennsylvania,
USA, Lot 3830066, Exp. date 11/85; Amphogel, Wyeth Laboratories,
Inc., Lot 3830068, Exp. date 11/85; Alternagel, Stuart Pharmaceuticals,
Wilmington, Delaware, USA, Lot 5125Y, Exp. date 12/86; Alu-Cap,
Riker Laboratories, Inc., Northridge, California, USA, Lot 37759, Exp.
date 8/86; Alu-Tab, Riker Laboratories, Inc., Lot 38353, Exp. date
10/87.
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and diluted to 60 muter with distilled water. Approximately 10
muter was filtered through a 0.45 micron membrane filter. Two
milliliters of the filtrate was diluted to 100 mliter and a 2 muter
aliquot was used to assay for phosphorous by the heteropoly
blue method [27]. The amount of phosphorous bound was taken
as the difference between the amount of phosphorous added (60
mg) and the amount remaining in the supernatant. A blank was
run using 2 mliter of water in place of the phosphate binding gel
sample to verify that no phosphorous was lost during experi-
mental manipulation.
The surface area of gibbsite and boehmite was determined by
the triple point gas adsorption method (Quantasorb, Quanta-
chrome Corp., Greenvale, New York, USA).
Results
Fig. 1. Transmission electron micrograph of gibbsite (A) and hoehmite
(B) at 170,000 x. Used with permission from [19J.
as were gibbsite2 and boehmite3. The products were obtained in
June 1984 and tested during June and July 1984. The aluminum
hydroxide content of the recommended dose of each product
was determined by chelatometric titration [201 and expressed as
the equivalent aluminum oxide content. The equivalent alumi-
num oxide content of gibbsite and boehmite was based on their
chemical formulas, Al(OH)3 and AIOOH, respectively. The
density of the suspensions was determined by pycnometry and
used to calculate the wt of a 10 mliter dose. The wt of the solid
dosage forms was taken as the average wt of 10 tablets or the
average wt of the contents of 10 capsules.
The fraction of the dose expected to be converted to soluble
aluminum species in the stomach was determined by pH-stat
titration4 at pH 2 or 3, 37°C [211. pH 3 was chosen because
correlation with in vivo acid neutralization has been established
[22]. Trials were also conducted at pH 2 because the pH of the
gastric contents may be as low as pH 1 [231.
The following procedure was used to determine the phos-
phate binding capacity in the intestine after exposure to gastric
conditions. A sample equal to 1/5 of the recommended dose was
added to 20 mliter of water (1/5 of the normal gastric fluid vol)
in a 100 mliter jacketed beaker at 37°C. The pH-stat titrator was
adjusted to maintain pH 3 for 15 mm with stirring. The
minimum gastric residence time of antacids is estimated to be 15
mm [181. The pH was then raised to 7.5, the pH of the small
intestine [24], by addition of 1 N NaOH. Twenty milliliters of a
0,3% phosphorous solution (3.182 g K3P04/1000 mliter) (1/5 of
the recommended phosphorous content of a meal) [25] was
added and the pH-stat titrator adjusted to maintain pH 7.5, 37°C
for three hr with stirring (the minimum residence time in the
small intestine is estimated to be three hours) [26]. The super-
natant was collected by centrifugation at 6000 rpm for 15 mm
2Gibbsite, Reynolds Metals Co., Bauxite, Arkansas, USA.
3Boehmite 1, Reynolds Metals Co.; Boehmite 11, Catapol SB Alumina,
sample no. 8250N, Continental Oil Co., Ponca City, Oklahoma, USA.
4PHM 62, TTT 60, ABU 12 (2.5 ml), TTA 60, REA 160, Radiometer,
Copenhagen, Denmark.
The aluminum content of each product is expressed as the mg
of equivalent aluminum oxide per dose in Table 1. The assayed
aluminum content per dose ranged from 659 to 420 mg of
equivalent aluminum oxide. A dose of 1.5 g was selected for
boehmite and gibbsite based on the wt per dose of Alu-Cap and
Alu-Tab.
The assay results are also compared to the label claim in
Table I. Although good agreement between the label claim and
the assay was obtained for each product, the terms used by
manufacturers to express the label claim can easily lead to
confusion. Three of the products expressed the content as mg of
dried aluminum hydroxide gel USP (1 mg dried aluminum
hydroxide gel USP contains 0.500 to 0.575 mg of equivalent
aluminum oxide). The other two products were labeled as mg of
aluminum hydroxide, Al(OH)3 (I mg Al(OH)3 is equivalent to
0.654 mg aluminum oxide). For clarity it is recommended that
all products use the same system to label the contents, A similar
problem was recently noted in the labeling of antacid suspen-
sions [28].
Figure 2 shows that the rate of acid neutralization at pH 3,
37°C varied widely for the commercial phosphate binders.
Basaljel, Amphogel and Alternagel reacted completely in 25, 30
and 50 mm, respectively while Alu-Cap and Alu-Tab only
achieved 80 and 35% neutralization in one hr. The crystalline
forms of aluminum hydroxide, boehmite, and gibbsite, were
virtually unreactive in simulated gastric conditions for 1 hr. The
rate of acid neutralization of the commercial phosphate binders
increased when tested at pH 2, 37°C. However, no change in
the rate of acid neutralization was observed when the crystal-
line forms of aluminum hydroxide were tested at pH 2, 37°C.
pH-stat titration of antacids at pH 3, 37°C has been correlated
with in vivo acid neutralization [22]. Therefore, the amount of
soluble aluminum species produced during acid neutralization
at pH 3, 37° (Fig. 2) may be related to the in vivo production of
soluble aluminum species during the gastric residence time. As
seen in Table 2, the quantity of soluble aluminum species
produced in 15 mm during in vitro acid neutralization varied
from 382 to 26.4 mg of equivalent aluminum oxide per dose for
the commercial products. If the aluminum hydroxide
phosphate—binding gel remains in the stomach for longer than
the minimum estimated gastric residence time, there is a
substantial increase in the amount of soluble aluminum pro-
duced (Table 2). For example, the amount of aluminum solubil-
ized in I hr, compared to 15 mm, increases by afactor of 4.5 and
8.9 for Alternagel and Alu-Tab, respectively. As the gastric
B
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Table 1. Aluminum content of phosphate binders.
Product
Recommended
dose Wt/dose, g
Labeled equivalent
A1203/dose, mg
Assayed equivalent
Al203/dose, mg
Alu-Tab 2 tablets 1.73 600—690 659
Alternagel 10 muter 11.12 600—690 610
Basaljel 10 muter 10.56 523 517
Alu-Cap 2 capsules 1.23 475—546 502
Amphogel 10 muter 10.56 418 420
Boehmite I — 1.50 — 1274
Boehmite II — 1.50 — 1274
Gibbsite — 1.50 — 980
a)N
a)C
0
a)
C.)
a,
0
a)
-cI-
Time, minutes
Fig. 2. Rate of acid neutralization at pH 3, 37°C. Abbreviations are: A,
Basaljel; B, Amphojel; C, Alternagel; D, Alu-Cap; E, Alu-Tab; F,
Boehmite I, Boehmite II and Gibbsite.
Table 2. Soluble aluminum species produced during in vitro acid
neutralization at pH 3, 37°C.
Product
Equivalent Al,O,
solubilized, %
15 mm 60 mm
Equivalent A120,
solubilized per dose, mg
is mm 60 mm
Basaljel 74.0 100. 382 517
Amphogel 68.0 100. 286 420
Alternagel 22.3 100. 136 610
Alu-Cap 24.1 78.4 121 393
Alu-Tab 4.01 35.6 26.4 235
Boehmite I 1.67 3.00 21.2 38.2
Boehmite II 1.04 2.00 13.3 25.5
Gibbsite 0.135 0.50 1.33 4.9
residence time varies depending on the volume and composition
of gastric contents and the patient's emotional state [29],
chronic renal failure patients may be exposed to higher soluble
aluminum concentrations as the gastric residence time in-
creases. In addition, the acidity of the gastric contents also
varies from pH 1.0 to 3.5 [23]. pH-stat titration at pH 2 indicates
that patients whose gastric pH is below 3 may be exposed to
greater concentrations of soluble aluminum when they take the
commercial phosphate binders than is projected in Table 2.
Boehmite and gibbsite, the crystalline forms of aluminum
hydroxide studied, generate a very small amount of soluble
aluminum species even though the equivalent aluminum oxide
content per dose was two to three times larger than the
commercial products (Table 2). Unlike the commercial prod-
ucts, gastric residence time or gastric pH is expected to have
little effect on the dissolution of gibbsite and boehmite due to
their low, zero—order dissolution rate (Fig. 2). It is assumed that
most of the dose of Basaljel and Amphogel leaves the stomach
as soluble aluminum species even after the minimum gastric
residence time. For the other commercial products, the amount
leaving the stomach as soluble aluminum species increases
substantially with increased gastric residence time or lower
gastric pH.
Aluminum hydroxide precipitates in the pH region above 4.5
and below 9.5 [16]. Thus, the soluble aluminum species pro-
duced by acid neutralization in the stomach may reprecipitate
when the higher pH of the intestine is encountered. The total
phosphate binding capacity is the sum of the phosphate
adsorbed by aluminum hydroxide particles and the phosphate
precipitated as aluminum phosphate due to reaction of soluble
aluminum species with phosphate. Thus, the phosphate binding
capacity was determined after the aluminum hydroxide was
exposed to pH conditions simulating the stomach followed by
an increase in pH to simulate passage into the small intestine.
The phosphate binding capacity of each product is given in
Table 3. Amphogel, Alternagel and Basaljel acted similarly,
removing the greatest amount of phosphate from solution. It is
interesting to note that boehmite adsorbed an amount of phos-
phate similar to that removed from solution by Alu-Tab or
Alu-Cap. Notice also that Amphogel and Basaljel, the products
producing the greatest fraction of soluble aluminum at pH 3,
had the largest standard deviation in phosphate binding capac-
ity. This higher variability is believed to be due to the uncon-
trolled precipitation of soluble aluminum species when the pH
was raised to 7.5. Precipitation under nonhomogeneous condi-
tions produces a wide distribution of aluminum hydroxide
polymers with different surface areas [16]. Such variability in
phosphate binding capacity of aluminum hydroxides which are
extensively neutralized could also be expected in vivo since the
environment of the small intestine is variable and nonhomo-
geneous.
The surface areas of the crystalline aluminum hydroxides,
being powders, could be determined by gas adsorption and
were the following: gibbsite, 5 m/g; boehmite I, 250 m2/g;
boehmite II, 281 m2/g.
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Product % Phosphate bounda SD
Amphogel 41.7 7.4
Alternagel 39.9 1.0
Basaljel 36.6 6.1
Alu-Tab 10.8 0.2
Alu-Cap 9.86 1.0
Boehmite II 11.6 0.0
Boehmite I 11.0 0.1
Gibbsite 0.160 0.2
Blank 0.00 —
a Average of two trials.
Table 4. Relationship between surface area of crystalline forms of
aluminum hydroxide and in vitro phosphate binding capacity
following simulated exposure to the stomach and small intestine.
% Phosphate bounda SD
Gibbsite 5 0.16 0.23
Boehmite I 250 11.0 0.14
Boehmite II 281 11.6 0.00
Discussion
Aluminum hydroxide can reduce the soluble phosphate con-
tent of the intestine by two major mechanisms: adsorption to
the surface of aluminum hydroxide particles; and formation of
insoluble aluminum phosphate by the reaction of soluble alu-
minum species with phosphate ions. Aluminum hydroxide
particles will be present in the intestine if the aluminum
hydroxide was not neutralized by gastric acid during its gastric
residence time or if soluble aluminum species, produced by
neutralization during the gastric residence time, precipitate in
the intestine due to the elevated pH. Aluminum hydroxide
particles in the intestine will bind phosphate only by adsorption.
The adsorption of phosphate by aluminum hydroxide is ex-
pected to be directly related to surface area as phosphate is
specifically adsorbed [13]. This relationship can be seen in
Table 4 where the surface area of the crystalline forms of
aluminum hydroxide is related to the extent of phosphate
binding. Boehmite II exhibits the highest surface area and
adsorbs more phosphate then either boehmite I or gibbsite.
When the aluminum hydroxide is neutralized by gastric acid,
phosphate binding in the intestine may occur by adsorption on
any reprecipitated aluminum hydroxide particles and by forma-
tion of insoluble aluminum phosphate. However, the soluble
aluminum species may also be systematically absorbed. The
surface area of the aluminum hydroxide is important in the
production of soluble aluminum species because the rate of acid
neutralization is directly related to surface area. Aluminum
hydroxides having a high surface area will be more rapidly
neutralized thus will produce more soluble aluminum species
during the gastric residence time.
The nonhomogenous conditions of the intestine can lead to
variations in both the extent of reprecipitation of soluble
aluminum species and the surface area of the reprecipitated
aluminum hydroxide. It can be seen in Table 3 that a greater
standard deviation in the amount of phosphate bound is asso-
ciated with the aluminum hydroxides which were extensively
neutralized, that is, Amphogel and Basaljel. The variability of
reprecipitation of aluminum hydroxide in the intestine may
account for the difference between the phosphate binding seen
for Alternagel and Alu-Cap even though both products were
solubilized to nearly the same extent by gastric acid. The
difference may also be due to differences in the surface area of
the unneutralized fraction of the aluminum hydroxide. There-
fore, aluminum hydroxides that are essentially unneutralized in
the stomach are expected to remove phosphate by adsorption.
Aluminum hydroxides which are extensively neutralized by
gastric acid will remove phosphate through formation of alumi-
num phosphate and, if reprecipitation occurs in the small
intestine, through adsorption also.
A phosphate binding gel which successfully balances phos-
phate adsorption and aluminum toxicity is a crystalline alumi-
num hydroxide of small enough surface area to undergo limited
neutralization during the gastric residence time, but having
enough surface area to adsorb an adequate amount of phos-
phate. At present, there are no commercial products available
which were designed as phosphate binders. Rather, aluminum
hydroxide antacids are administered to renal failure patients to
reduce serum phosphate levels. These products are required to
pass the Food and Drug Administration's Preliminary Antacid
Test [30], thus insuring that soluble aluminum species are
produced in gastric acid. Antacid action is not required for
phosphate binding, as phosphate can be adsorbed by aluminum
hydroxide particles and may be undesirable since acid neutral-
ization leads to formation of soluble aluminum species which
have the potential to induce aluminum toxicity.
In the future, products should be specifically designed as
nonantacid phosphate binders. The behavior of boehmite sug-
gests that higher surface area, crystalline forms of aluminum
hydroxide should be further investigated as possible phosphate
binding agents.
Reprint requests to Stanley L. Hem, Ph.D., Department of Industrial
& Physical Pharmacy, Purdue University, Pharmacy Building, West
Lafayette, Indiana 47907, U.S.A.
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